Pds Biotechnology CORP 8-K filings

PDS Biotechnology Corporation announced that its stockholders approved an amendment to its 2014 Equity Incentive Plan, increasing the share pool by over 3.1 million shares, and re-elected two Class A directors at its 2025 Annual Meeting.

PDS Biotechnology Corporation announced updated positive data from its VERSATILE-002 trial and other studies for Versamune HPV (PDS0101) in treating HPV16-positive head and neck cancers, presented at the 2025 ASCO Annual Meeting.

PDS Biotechnology announces positive extended follow-up data for VERSATILE-002 and additional trials evaluating Versamune HPV to be presented at the 2025 ASCO Annual Meeting.

PDS Biotechnology Corporation reported its Q1 2025 financial results, highlighted by the progress of the VERSATILE-003 Phase 3 clinical trial and upcoming presentations at ASCO.

PDS Biotechnology highlights promising preclinical results for its Infectimune-based universal flu vaccine at the IMMUNOLOGY2025 Annual Meeting, showcasing broad immune response against multiple influenza strains.

PDS Biotechnology Corporation enters into a securities purchase agreement for $20 million, issuing senior secured convertible debentures and warrants to strengthen its financial position.

Sir Richard Sykes will retire from the Board of Directors of PDS Biotechnology Corporation at the 2025 Annual Meeting of Stockholders.

PDS Biotechnology reports its full year 2024 financial results and provides an update on its clinical programs, highlighted by the initiation of a Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer.

PDS Biotechnology announces FDA clearance of its IND application for a combination therapy targeting MUC1-positive metastatic colorectal cancer.

PDS Biotechnology initiates the VERSATILE-003 Phase 3 clinical trial to evaluate Versamune HPV in HPV16-positive head and neck cancer.

PDS Biotechnology Corporation has announced a registered direct offering to raise $11 million upfront, with the possibility of an additional $11 million upon full warrant exercise.

PDS Biotechnology announces the publication of positive clinical data in JAMA Oncology, showcasing promising survival and clinical responses in patients with recurrent/metastatic HPV-associated cancers treated with a triple combination therapy.

PDS Biotechnology announces positive circulating tumor DNA results for Versamune HPV, indicating potential as a broadly effective treatment for HPV16-associated cancers and plans for a Phase 3 trial in HPV16-positive HNSCC.

PDS Biotechnology reaffirms its plan to initiate the VERSATILE-003 Phase 3 clinical trial for Versamune HPV plus pembrolizumab in first-line treatment of recurrent and/or metastatic HPV16-positive head and neck squamous cell cancer (HNSCC) in Q1 2025.

PDS Biotechnology Corporation provided a business update, reported its third quarter 2024 financial results, and announced modifications to its Phase 3 trial design for its lead candidate, Versamune HPV.

PDS Biotechnology reports an 84.4% overall survival rate at 36 months for locally advanced cervical cancer patients treated with Versamune HPV and chemoradiation in a Phase 2 trial.

PDS Biotechnology Corporation is progressing its cancer immunotherapy programs, highlighted by positive Phase 2 results for Versamune HPV in head and neck cancer and the planned initiation of a Phase 3 trial.

PDS Biotechnology reported updated data from its VERSATILE-002 trial, showing promising results for its Versamune HPV treatment in combination with pembrolizumab for head and neck cancer.

PDS Biotechnology Corporation has amended its at-the-market offering agreement to allow for the potential sale of up to $50 million in common stock.

PDS Biotechnology reports alignment with the FDA on a Phase 3 trial design for their lead candidate and announces second quarter 2024 financial results with reduced operating expenses.

PDS Biotechnology will present updated Phase 2 clinical trial data for its Versamune HPV treatment in combination with chemoradiation for locally advanced cervical cancer at the 2024 ASTRO Annual Meeting.

PDS Biotechnology Corporation will release its second quarter 2024 financial results and provide a business update on August 13, 2024, before the market opens.

PDS Biotechnology Corporation announced that an abstract featuring updated data from the VERSATILE-002 trial of Versamune HPV in combination with KEYTRUDA for head and neck cancer has been accepted for presentation at the ESMO Congress 2024.

PDS Biotechnology has received FDA agreement on the design of its Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer, with the trial expected to begin in Q4 2024.

PDS Biotechnology's stockholders approved an increase in authorized common stock and elected two Class C directors at their 2024 annual meeting.

PDS Biotechnology reported a median overall survival of 30 months in its VERSATILE-002 Phase 2 clinical trial for head and neck cancer, with many patients approaching three years of follow-up.

PDS Biotechnology reported positive updated data from its Phase 2 VERSATILE-002 clinical trial and its first quarter 2024 financial results, highlighting progress in its cancer immunotherapy programs.

PDS Biotechnology's VERSATILE-002 Phase 2 trial demonstrated a 30-month median overall survival in first-line recurrent/metastatic HPV16-positive head and neck cancer, significantly exceeding historical benchmarks.

PDS Biotechnology is progressing its cancer immunotherapy programs, showcasing encouraging survival data and plans for pivotal trials in head and neck cancer.

PDS Biotechnology Corporation has appointed Stephan Toutain as its new Chief Operating Officer, effective May 1, 2024, and granted him a stock option as an inducement.